Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Registered voters: 125,090 valid: 104,941 turnout: 84% The West Prussian plebiscite area remained with Germany and became part of the new West Prussia Government Region, which was annexed to East Prussia in 1922.
=== Weight harnesses === When large amounts of weight are needed, a harness may be used to carry the load on the diver's shoulders, rather than around the waist, where it may tend to slip down into an uncomfortable position if the diver is working in a vertical posture, which is often the case. Sometimes this is a separate harness, worn under the safety harness, with pockets at the sides to carry the weights, and sometimes it is an integrated system, which carries the weight in pockets built into or externally attached to the safety harness. On the standard diving suit, the load of the weighting system was usually at least partly transferred to the corselet of the copper helmet, to directly counteract the helmet's buoyancy.
Electron-capture dissociation (ECD) — A mass spectrometry fragmentation technique for sequencing proteins and peptides. Isotopic resonance hypothesis — Proposes that specific isotopic compositions can accelerate biochemical reactions. Experimental studies on Escherichia coli growth have supported aspects of the hypothesis. Proteomics and biomarkers — Discovery of proteomic signatures in neurodegenerative diseases such as Alzheimer’s disease, along with developments in immunoproteomics and molecular biometry. Origin of life experiments — Research showing that abiotically synthesized mixtures, such as those produced in Miller–Urey type experiments, can sustain bacterial growth.
The vapor pressure is the equilibrium pressure from a liquid or a solid at a specific temperature. The equilibrium vapor pressure of a liquid or solid is not affected by the amount of contact with the liquid or solid interface. The normal boiling point of a liquid is the temperature at which the vapor pressure is equal to normal atmospheric pressure. For two-phase systems (e.g., two liquid phases), the vapor pressure of the individual phases are equal. In the absence of stronger inter-species attractions between like-like or like-unlike molecules, the vapor pressure follows Raoult's law, which states that the partial pressure of each component is the product of the vapor pressure of the pure component and its mole fraction in the mixture. The total vapor pressure is the sum of the component partial pressures.
Sources: en.wikipedia.org
The measurements included one with a range from about 4,250 to about 4,390 years ago, and another with a range from about 4,520 to about 4,690. Errors in procedure can also lead to errors in the results. If 1% of the benzene in a modern reference sample accidentally evaporates, scintillation counting will give a radiocarbon age that is too young by about 80 years.
The first long-acting analogue, insulin glargine, was approved in 2000. Insulin aspart, insulin glulisine, and insulin detemir were all approved by 2005. The second wave of insulin analogues, which include insulin degludec and insulin icodec, started in the 2010s. Insulin analogues are on the World Health Organization's List of Essential Medicines.
In late August 2008, Georgian president Saakashvili said that he expected threat from Abkhazia and had most of the forces stationed near Abkhazia, adding: "if we'd intended to attack, we'd have withdrawn our best-trained forces from Iraq up front." He also said that he had been told in Dubrovnik that Russia would attack Georgia in the summer of 2008. By late August, President Saakashvili said that before the war, he had warned Western leaders (among them U.S. Secretary of State Condoleezza Rice and German Chancellor Angela Merkel) about Russia's intentions to invade Georgia; however his warnings were not taken into account. The Georgian authorities were aware that the United States would not become militarily involved in the conflict with Russia. On 31 August, President Saakashvili told the CNN that he supported neutral international investigation into the causes of the war. He further said that Putin had threatened with the war in the fall of 2006 before the announcement of trade embargo against Georgia. In September 2008, former Russian president Vladimir Putin said the war began during the second half of 7 August and Russian military reached Tskhinvali in two days. Putin accused the United States of encouraging Georgian military attack. He added, "When an aggressor comes into your territory, you need to punch him in the face." Putin claimed there would be a "second blow" into the North Caucasus if Russia had not acted in Georgia.
"Validation. The assurance that a product, service, or system meets the needs of the customer and other identified stakeholders. It often involves acceptance and suitability with external customers. Contrast with verification." "Verification. The evaluation of whether or not a product, service, or system complies with a regulation, requirement, specification, or imposed condition. It is often an internal process. Contrast with validation." Similarly, for a Medical device, the FDA (21 CFR) defines Validation and Verification as procedures that ensures that the device fulfil their intended purpose.
== Production of a peptide microarray == A peptide microarray is a planar slide with peptides spotted onto it or assembled directly on the surface by in-situ synthesis. Whereas peptides spotted can undergo quality controls that include mass spectrometer analysis and concentration normalization before spotting and result from a single synthetic batch, peptides synthesized directly on the surface may suffer from batch-to-batch variation and limited quality control options. However, peptide synthesis on chip allows the parallel synthesis of tens of thousands of peptides providing larger peptide libraries paired with lower synthesis costs. Peptides are ideally covalently linked through a chemoselective bond leading to peptides with the same orientation for interaction profiling. Some alternative procedures describe unspecific covalent binding and adhesive immobilization. However, lithographic methods can be used to overcome the problem of excessive number of coupling cycles. Combinatorial synthesis of peptide arrays onto a microchip by laser printing has been described, where a modified colour laser printer is used in combination with conventional solid-phase peptide synthesis chemistry. Amino acids are immobilized within toner particles, and the peptides are printed onto the chip surface in consecutive, combinatorial layers. Melting of the toner upon the start of the coupling reaction ensures that delivery of the amino acids and the coupling reaction can be performed independently.
Sources: en.wikipedia.org
Oxycodone has a hydroxy group at carbon-14 (codeine has just a hydrogen in its place) Oxycodone has a 7,8-dihydro feature. Codeine has a double bond between those two carbons; and Oxycodone has a carbonyl group (as in ketones) in place of the hydroxyl group of codeine. It is also similar to hydrocodone, differing only in that it has a hydroxyl group at carbon-14.
=== Pharmacokinetics === Caspofungin is slowly metabolized by peptide hydrolysis and N-acetylation in liver. Therefore, in case of liver impairment the dose needs to be reduced. Caspofungin also undergoes spontaneous chemical degradation to an open-ring peptide compound, L-747969. Additional metabolism involves hydrolysis into constitutive amino acids and their derivatives, including dihydroxyhomotyrosine and N-acetyl-dihydroxyhomotyrosine.
== See also == Chirality (electromagnetism) Chirality (mathematics) Chirality (physics) Enantiopure drug Enantioselective synthesis Handedness Orientation (vector space) Pfeiffer effect Pseudochirality Stereochemistry for overview of stereochemistry in general Stereoisomerism Supramolecular chirality
=== Conflict between black groups === In the late 1980s and early 1990s, supporters of the UDF, ANC, and aligned militias were, in some areas, involved in prolonged low-intensity conflict with a constellation of various other militias: some independent, others state-sponsored, and many aligned to the rival Inkatha. In some accounts, this development was directly linked to events during the Vaal uprising: as the United Nations High Commissioner for Refugees observed in 1996, the uprising had led to the formation of local vigilantes and in some cases to territorial conflicts between them. "A degree of conflict between black groups" was already a feature of the uprising by 1985. In addition, the uprising also involved the seeds of hostility between UDF supporters and Inkatha, with Inkatha leader Mangosuthu Buthelezi stridently condemning the uprising's leaders and encouraging his supporters to retaliate against the perpetrators of violence.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.